Ignite Creation Date:
2025-12-24 @ 4:42 PM
Ignite Modification Date:
2025-12-28 @ 9:33 AM
Study NCT ID:
NCT00362466
Status:
TERMINATED
Last Update Posted:
2009-11-20
First Post:
2006-08-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
Sponsor:
Bristol-Myers Squibb
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2007-04
Start Date Type:
None
Primary Completion Date:
2008-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-06
Completion Date Type:
ACTUAL
First Submit Date:
2006-08-09
First Submit QC Date:
None
Study First Post Date:
2006-08-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2009-07-24
Results First Submit QC Date:
None
Results First Post Date:
2009-09-03
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2009-11-18
Last Update Post Date:
2009-11-20
Last Update Post Date Type:
ESTIMATED